secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2021-10-12T23:59:59+00:00
Accession:  0001213900-21-052250
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics receives FDA IND clearance for TARA-002 in non-muscle invasive bladder cancer
--------------------------------------------------------------------------------

- FDA cleared IND for TARA-002, an investigational cell-based therapy for NMIBC.
- Phase 1 trial planned to initiate by year-end 2021 in high-grade NMIBC patients.
- TARA-002 manufactured from same cell bank as OK-432, approved in Japan and Taiwan.
- Confirmatory GMP-scale comparability data submitted and reviewed by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021052250/0001213900-21-052250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021052250/ea148683-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-052250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer